https://www.marketsandmarkets.com/Market-Reports/infectious-disease-diagnostics-market-116764589.html

The global infectious disease diagnostics market is projected to reach USD 19.35 Billion in 2022 from USD 14.73 Billion in 2017, at CAGR of 5.6%. Infectious disease diagnostics are various techniques used by healthcare professionals to detect and diagnose diseases causing pathogens in human samples such as serum, blood, urine, throat swab, and stool. Growth in this market is largely be driven by the increasing global prevalence of infectious diseases, the shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

In this report, the market has been categorized based on product & service, disease type, technology, end user, and region.

The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service. The assays, kits, & reagents segment accounted for the largest share of the global infectious disease diagnostics market and is expected to register the highest CAGR during the forecast period. The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.

Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases. The hepatitis diagnostics segment accounted for the largest share of the global market in 2017. The dominant share of this segment can be attributed to the rising prevalence of hepatitis B and C, the availability of a large number of hepatitis diagnostic tests, and increasing number of HIV/Hepatitis co-infections.

The infectious disease diagnostics market is segmented into major seven technologies, namely, immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays, and other technologies. In 2017, the immunodiagnostics segment accounted for the largest share of the global market. The large share of this segment can be attributed to the increasing use of immunoassays in POC infectious disease testing, development of novel tests, rising trend of automation, and increasing awareness about health and fitness.

On the basis of end user, the global market is segmented into hospitals/clinical laboratories, reference laboratories, physician offices, academic/research institutes, and other end users. In 2017, the hospitals/clinical laboratories segment accounted for the largest share of the global market. Also, this segment is expected to grow at the highest CAGR during the forecast period due to the large number of diagnostic tests carried out in hospitals.

In 2017, in terms of value, North America accounted for the largest share of the global market. This large share can be attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

However, inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques are restraining market growth.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalyst.asp?id=116764589

The key players in the global infectious disease diagnostics market are Abbott (US), Becton, Dickinson and Company (BD) (US), biomérieux (France), Bio-Rad (US), and Roche (Switzerland). These players focus on inorganic strategies such as acquisitions, partnerships, agreements, collaborations and as well as organic strategies such as expansions and product launches & approvals to sustain their growth in the market.